GLP-1 drugs cut breast cancer risk by up to 30%

Studies presented at the American Society of Clinical Oncology’s annual meeting in Chicago found GLP-1 medications are linked to lower breast cancer incidence and death, and may reduce spread of several cancers. Researchers also stress the findings are not yet

For millions of people already taking GLP-1 medications to manage obesity, the news is both promising and complicated: in studies presented at the world’s largest oncology conference, the drugs were tied to meaningful reductions in breast cancer risk—and possibly benefits across other cancers too.

One analysis reported that people who took GLP-1 medications were 30% less likely to develop breast cancer—the most common form of the disease—compared with those not taking weight-loss drugs. A second study looked at people already living with breast cancer and found that adding weight-loss drugs to standard treatment reduced the risk of patients dying from the disease by 30%.

A third piece of research, covering patients with breast, lung, bowel or liver cancer, found those on weight-loss drugs were up to 50% less likely to have their disease spread.

The findings were shared at the American Society of Clinical Oncology’s annual meeting in Chicago.

The attention is landing on GLP‑1 medications because of what they do in the body. The drugs are a class of medications that mimic a natural hormone called glucagon‑like peptide‑1. which helps regulate blood sugar and appetite. Originally used to treat type 2 diabetes, they are now widely used for weight management.

In the first study—a retrospective analysis of 110. 000 women aged between 45 and 80—researchers found that women who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not. The results were presented by Dr Elizabeth McDonald. a professor of radiology at the University of Pennsylvania and a breast radiologist at the Abramson Cancer Center.

McDonald’s language was careful, even as the numbers drew attention. “While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence. it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”.

She also said GLP-1s were never built for cancer. “GLP-1 medications are intriguing from a cancer research perspective because they weren’t designed for cancer therapy. but they do affect many different targets and pathways associated with cancer development. so we’re eager to study them in this context.”.

That distinction matters because obesity—and what comes with it—has long been tied to breast cancer risk. The drugs’ effectiveness at helping people lose weight is well established. and maintaining a healthy weight has long been recommended as a way to ward off breast cancer. Researchers pointed out that being overweight or obese, particularly after menopause, is a known risk factor for breast cancer.

McDonald also described other biological reasoning beyond weight. Researchers have long suspected that low-grade inflammation may play a role in breast cancer development. GLP-1s reduce systemic inflammation via different pathways and can have other metabolic and epigenetic effects that could inhibit tumour growth. McDonald believes multiple effects of weight-loss drugs inhibit breast cancer development. “Ultimately, we want to find better options to prevent breast cancer. It’s been encouraging to see the survival rates for breast cancer improve over recent decades. and we’d love to see the same gains in prevention. ” she said.

The second study brought the question into the treatment setting. It involved 27. 000 breast cancer patients and was led by IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori. a cancer centre in Meldola. Italy. Adding weight-loss drugs to standard treatment was associated with a 30% reduced risk of death, researchers found.

The third study widened the lens further. It involved 12,000 cancer patients and was led by the Cleveland Clinic. Researchers reported that in lung. breast. bowel and liver cancer. people who took weight-loss drugs were 38% to 50% less likely to develop stage-four forms of the disease than people who did not.

Not everyone sees it as a simple weight-loss story.

Dr Marcin Chwistek. the director of the supportive oncology and palliative care programme at Fox Chase Cancer Center in Philadelphia. said: “GLP-1 receptor agonists have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects.”.

Dr Eleonora Teplinsky. the head of breast and gynaecologic medical oncology at Valley Health System in New Jersey. pointed to the gap that still sits between association and certainty. “The evidence was not clear yet as to whether the potential benefits of weight-loss drugs in the fight against cancer were just as a result of weight loss or due to other factors.”.

She said there is momentum but not a final answer. “I think there is enough data to show there is clearly some impact on either cancer risk or the risk of recurrence, but we haven’t yet defined it exactly,” she said. “We need to do more studies putting patients on them and seeing what happens.”

Teplinsky also described a practical reason interest is accelerating, beyond prevention and survival statistics. “There are also signals that they may help with side-effects. My patients who are on GLP-1s often feel better and it helps with a lot of the side-effects from their hormone blockers. Interest in this area is climbing exponentially. It’s a very hot topic right now and hopefully we can capitalise on that.”.

For now, the message coming out of Chicago is not a green light to treat cancer with GLP-1s. It is something more delicate: evidence that a widely used set of drugs may have an additional role in cancer prevention. treatment. and disease progression—evidence that is strong enough to justify the next question. and careful enough to admit what still isn’t proven.

GLP-1 weight-loss drugs breast cancer risk ASCO annual meeting Chicago obesity cancer prevention stage-four cancer hormone blockers inflammation glucagon-like peptide-1